Download PDF
Horm Metab Res 1987; 19(12): 636-641
DOI: 10.1055/s-2007-1011898
Clinical

© Georg Thieme Verlag, Stuttgart · New York

Effect of Growth Hormone-Releasing Hormone and Clonidine on Growth Hormone Release in Type 1 Diabetic Patients

O. Giampietro1 , M. Ferdeghini2 , R. Miccoli1 , V. Locatelli4 , M. Cerri1 , N. Yanaihara3 , R. Navalesi1 , E. E. Müller4
  • 1Chair of Metabolic Diseases, Institute of the 2nd Medical Clinic, University of Pisa, Pisa, Italy
  • 2Center of Nuclear Medicine, University of Pisa, Pisa, Italy;
  • 3Shizouka College of Pharmacy, Shizouka, Japan;
  • 4Department of Pharmacology, University of Milan, Milan, Italy
Further Information

Publication History

1987

1987

Publication Date:
14 March 2008 (online)

Also available at
  PDF Download  Permissions and Reprints

Summary

We administered growth-hormone releasing hormone (GHRH), clonidine or thyrotropin-releasing hormone (TRH) as intravenous boli each in three different randomized mornings to nine well-controlled Type 1 diabetic men and to six age-matched healthy men who served as controls. GHRH and clonidine evoked a prompt and brisk GH release both in diabetic and in control subjects with no significant difference being evident between the two groups. Only one diabetic subject showed a paradoxical GH release after TRH when he was under long-term poor metabolic control.

These results indicate that in insulin-dependent patients with good control of the metabolic disease the response of somatotropes to pituitary- or central nervous system-directed stimuli is normal. These data are supportive of the idea that altered GH secretion in Type 1 diabetes rather than reflecting a primary hypothalamic and/or pituitary alteration may be a state-dependent phenomenon related to the metabolic state of the disease.

Key-Words

Growth-Hormone Releasing Hormone - Clonidine - hGH - Diabetes Mellitus

      >